Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exact Sciences

Markets Today: Stocks Rally as U.S. CPI Eases

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.37%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.45%. U.S. stock index futures this morning erased overnight losses and pushed higher after U.S. consumer prices eased in April. Bond yields also fell on the...

Barchart

Exact Sciences, Guardant Health Put Up Big Sales Beats As They Target The 'Most Preventable' Cancer

Exact Sciences delivered a first-quarter report that "checked all the boxes," an analyst said as EXAS stock surged.

Investors Business Daily

Dow Jones Reverses Ahead Of Fed Minutes; Baidu Surges On Earnings; Nvidia Earnings On Deck

The Dow Jones reversed lower Wednesday ahead of minutes from the Federal Reserve's latest policy meeting. Nvidia earnings are due out late.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures Rise: S&P 500 Nears Key Support As Nvidia Earnings Loom; Here's What To Do Now

The Nasdaq and S&P 500 have tumbled to just above critical support as Treasury yields spike. Nvidia earnings are on tap.

Investors Business Daily

Exact Sciences, A Top 5% Stock, Beat Quarterly Expectations

Exact Sciences delivered a second consecutive quarter of sales growth acceleration and EXAS stock rose on Wednesday.

Investors Business Daily

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Investors Business Daily

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review

The stock market rally picked up steam amid cooler inflation. Sharp Tesla price cuts and some notable earnings were in focus.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Exact Sciences Raises Fourth-Quarter Estimates Above Expectations

EXAS stock jumped as the provider of cancer screening and diagnostic tests raised estimates for its fourth quarter.

Investors Business Daily

Exact Sciences Stock Scores Relative Strength Rating Upgrade

Exact Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Stock Market Closes Near Day's Lows As S&P Falls Below Key Level On Recession Concerns

The stock market extended losses to a third day on low business activity and fears of a global recession. Facebook bucked the trend.

Investors Business Daily

Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

Investors Business Daily

Cathie Wood Has Bet Big On These 10 Stocks; Here's How They Performed In 2022

Cathie Wood makes big bets on potential huge winners. But Ark Invest's top 10 holdings, including Tesla and Roku, tumbled in 2022.

Investors Business Daily

Exact Sciences Surges After Massively Beating Quarterly Forecasts, Raising Outlook

Exact Sciences massively beat third-quarter expectations and raised its full-year outlook — and EXAS stock skyrocketed on Friday.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022

Upgrades

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Next-gen blood tests to detect cancer and other diseases come with questions

The tests can help detect some diseases early but it's still unclear how much they affect whether someone survives a disease.

Benzinga

Expert Ratings for Exact Sciences

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Benzinga

Exact Sciences's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

Benzinga

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.

Benzinga

Preview: Exact Sciences's Earnings

Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Exact Sciences will report an earnings per share (EPS) of $-1.07.

Benzinga

Analyst Ratings for Exact Sciences

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Benzinga

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.

StockNews.com

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis.

Benzinga

Where Exact Sciences Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.